- Bristol Myers Squibb - Bristol Myers Squibb’s Investigational LPA1 . . .
BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA 1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- Phase 2 trial design of BMS-986278, a lysophosphatidic acid . . . - PubMed
BMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD Methods and analysis: This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD
- American Journal of Respiratory and Critical Care Medicine
This phase 2 study evaluated the efficacy and safety of admilparant (BMS-986278), a second-generation, oral LPA 1 antagonist, in parallel arms of patients with either IPF or PPF, including those concurrently receiving background antifibrotic treatment
- BMS-986278 declared breakthrough therapy for progressive PF
The U S Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb ’s investigational therapy for progressive pulmonary fibrosis (PF)
- Phase 2 trial design of BMS- 986278, a lysophosphatidic acid receptor 1 . . .
METHODS AND ANALYSIS Study design and interventions NCT04308681 is a phase 2, randomised, double- blind, placebo- controlled, international clinical study investi-gating the efficacy, safety, and tolerability of BMS- 986278 in patients with either IPF or PF- ILD in parallel arms
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS . . .
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis
- BMS-986278 | LPL Receptor Antagonist | MedChemExpress
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6 9 nM and 4 0 nM for human and mouse LPA1, respectively BMS-986278 can be used for the research of pulmonary fibrotic diseases - Mechanism of Action Protocol
- Efficacy and Safety of Admilparant, an LPA - PubMed
Objectives: Assess efficacy and safety of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with IPF and PPF
|